Shots: The P-III ORIENT-3 trial involves assessing the efficacy and safety of Tyvyt (sintilimab) vs docetaxel (q3w) in 290 patients in a ratio (1:1) as a 2L treatment for advanced […]readmore
Tags : 2L
Shots: The approval is based on P-II Brigatinib-2001 (J-ALTA) assessing Alunbrig in 72 Japanese patients with ALK+ NSCLC and P-III AP26113-13-301 (ALTA-1L) study assessing Alunbrig (180mg, qd with seven-day lead-in […]readmore
Shots: The approval is based on P-II L-MIND study assessing Monjuvi in combination with lenalidomide as a treatment for adult patients with relapsed or refractory DLBCL Results: ORR (55%); CR […]readmore
Shots: The approval is based on P-III KEYNOTE-181 study assessing Keytruda vs CT in previously treated patients with recurrent or metastatic ESCC whose tumors expressed PD-L1 (CPS ≥10) and data […]readmore
Shots:sstosohShots: The P-II ORIENT-2 study involves assessing TYVYT as monothx. vs paclitaxel/ rinotecan in 190 patients in a ratio (1:1) with advanced or metastatic ESCC who failed 1L treatment The […]readmore
Shots: Shots: The ongoing P-II study involves assessing Libtayo (300mg, IV, q3w) for up to 93 wks. or until disease progression, unacceptable toxicity, withdrawal of consent or confirmed complete response […]readmore
Shots: The approval follows the P-II study which involves assessing of Trodelvy in 108 adults with TNBC who had previously received a median of three prior systemic therapies in the […]readmore
Shots: The approval is based on P-II BGB-A317-203 (NCT03209973) trial which involves assessing of tislelizumab with median follow up of 14 months The study resulted in ORR as 76.9% and […]readmore
Shots: The approval is based on P-III CELESTIAL trial result assessing Cabometyx (60 mg qd) vs PBO in 760 patients in ratio (2:1) with advanced HCC receiving 2L treatment & […]readmore
Shots: The P-III KEYNOTE-181 study involves assessing of Keytruda monothx vs CT in 600 patients in ratio (1:1) receiving (Keytruda 200 mg FD q3w) or IV CT (docetaxel /paclitaxel/ irinotecan) […]readmore